RE:RE:PwC sees continuation of US$ 5 to 15 Billion Bio M&A Dealsrepost - June 20, 2024 - "“As dealmakers become more comfortable with regulatory uncertainty, we’ve seen dealmakers increasingly focused on deals in the $5 billion to $15 billion range rather than in large-scale transformative M&A,” Roel Van den Akker, PwC’s Pharma and Life Sciences Seals Lead, said over email. “Significant progress in innovation continues and we expect to see continued robust deal activity in late 2024 and into 2025.”
https://www.fiercebiotech.com/biotech/biopharma-dealmaking-continues-rise-ma-values-hold-steady-pwc
February 01 2024 - Merck's (MSD) CEO Robert Davis went on record by saying that Merck's acquisition "sweet spot " is US$ 10+ Billion, as had been suggested as Big Pharma's sweet spot around 12 month ago.
During JPM 2024 Davis and research chief Dean Li, M.D., Ph.D., remained consistent with previous comments that dealmaking decisions are led by the best science, not the best financial opportunity. Davis says is it just so happens that Merck's "sweet spot" have been deals in the $0-15 billion range. The New Jersey pharma acquired immunology biotech Prometheus for $10.8 billion and is paying Daichii Sankyo at least $5.5 billion over two years for a batch of antibody-drug conjugates.
Now think of the future, and precision medicine and the development of an I/O combination therapy, involving a bi or trispecific or ADC, in combination with pembrolizumab and ONCY's pelareorep, for the treatment of multiple cancers. This future is fast approaching.